Open sidebar
Focus
Aduhelm
Dementia & Alzheimer's
|
George Citroner
Many Ineligible for New Alzheimer's Drugs: Study
A new class of Alzheimer's drugs offers hope of slowing cognitive decline, but emerging research shows only a fraction of patients may qualify for these potentially life-changing treatments.
Aug 28, 2023
|
George Citroner
Aug 28
|
US News
|
Katabella Roberts
FDA's Approval Process of Controversial Alzheimer's Drug Was 'Rife With Irregularities': Congressional Probe
Dec 30, 2022
|
Katabella Roberts
Dec 30
|
Policies & Impacts
|
Katabella Roberts
Biden Touts Reduction of 2023 Medicare Fees, Due Largely to Limiting of Alzheimer's Drug
Sep 28, 2022
|
Katabella Roberts
Sep 28
|
Medicine
|
Health 1+1
,
Kelly Song
FDA Finally Approved an Alzheimer's Drug—But Everything Surrounding It Is Controversial
Aug 20, 2022
|
Health 1+1
Aug 20
|
Health Care
|
Marina Zhang
Fixed Packaging of Alzheimer’s Drug May Waste $605 Million a Year for Medicare, Experts Warn
Jul 06, 2022
|
Marina Zhang
Jul 06
|
Companies
|
Reuters
Biogen CEO to Step Down, Drugmaker Pulls Back on Alzheimer's Drug Aduhelm
May 04, 2022
|
Reuters
May 04
|
Health News
|
Zachary Stieber
Medicare Officially Limits Coverage of Alzheimer's Drug to Those in Clinical Trials
Apr 08, 2022
|
Zachary Stieber
Apr 08
|
Executive Branch
|
Zachary Stieber
Biden Administration Decides to Limit Medicare Coverage of New Alzheimer's Drug
Jan 11, 2022
|
Zachary Stieber
Jan 11
|
Executive Branch
|
Zachary Stieber
CMS May Review Medicare Premium in Light of Aduhelm Price Drop
Jan 10, 2022
|
Zachary Stieber
Jan 10
|
Health
|
Reuters
Biogen Halves Price of Alzheimer's Drug to $28,200
Dec 20, 2021
|
Reuters
Dec 20
|